valemetostat (Ezharmia) Report issue

Small molecule Experimental
AACT

Active Ingredient History

NOW
  • Now

Chemistry

  • SMILES: Cc1cc(C)c(CNC(=O)c2cc(Cl)c3c(c2C)O[C@@](C)([C@H]2CC[C@H](N(C)C)CC2)O3)c(=O)[nH]1.Cc1ccc(S(=O)(=O)O)cc1
  • InChIKey: JSBKGJUYSLVFPF-WJQUPPJOSA-N
  • Mol. Mass: 660.23
  • ALogP: 4.49
  • ChEMBL Molecules:
    valemetostat tosylate  
    valemetostat  
More Chemistry

Pharmacology

Alternative names

ds-3201b

Organizations (6)

Research & Development (6)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (19)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (19)


 

Breast Neoplasms (Phase 1)

Carcinoma, Non-Small-Cell Lung (Phase 1/Phase 2)

Carcinoma, Renal Cell (Phase 1)

Carcinoma, Transitional Cell (Phase 1)

Head and Neck Neoplasms (Phase 1/Phase 2)

Leukemia-Lymphoma, Adult T-Cell (Phase 2)

Leukemia, Myeloid, Acute (Phase 1)

Liver Diseases (Phase 1)

Lung Neoplasms (Phase 1/Phase 2)

Lymphoma (Phase 1/Phase 2)

Lymphoma, B-Cell (Phase 2)

Lymphoma, Non-Hodgkin (Phase 1)

Lymphoma, T-Cell (Phase 2)

Neoplasms (Phase 1/Phase 2)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 1)

Prostatic Neoplasms (Phase 1)

Prostatic Neoplasms, Castration-Resistant (Phase 1)

Small Cell Lung Carcinoma (Phase 1/Phase 2)

Squamous Cell Carcinoma of Head and Neck (Phase 1/Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 11
  • # of Trial Organizations: 6

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue